Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.65 |
| ▸ | AR | P10275 | 3/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30741714 | 0.92 | CRBN (0.69) | CRBNDDB1ARHPGDSGSPT1 | |
| SCHEMBL23729513 | 0.92 | CRBN (0.69) | CRBNDDB1ARHPGDSGSPT1 | |
| SCHEMBL30805408 | 0.88 | CRBN (0.70) | CRBNDDB1ARHPGDSGSPT1 | |
| SCHEMBL23173248 | 0.87 | CRBN (0.64) | CRBNDDB1ARHPGDS | |
| SCHEMBL30741730 | 0.87 | CRBN (0.68) | CRBNDDB1ARHPGDSRAF1 | |
| SCHEMBL22291243 | 0.87 | CRBN (0.68) | CRBNDDB1ARHPGDSRAF1 | |
| SCHEMBL27035744 | 0.87 | CRBN (0.69) | CRBNDDB1ARHPGDSGSPT1 | |
| SCHEMBL24420981 | 0.86 | CRBN (0.58) | CRBNDDB1AR | |
| SCHEMBL29614670 | 0.86 | CRBN (0.58) | CRBNDDB1AR | |
| SCHEMBL24822626 | 0.85 | CRBN (0.79) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025021075-A1 | NSD PROTEIN DEGRADATION AGENT AND USE THEREOF | 中国科学院上海有机化学研究所 | 2025-01-30 | — | — | WO | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | TYK2, CRBN, CSNK2A3 | CRBN 2/4885DDB1 1322/4885AR 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.